Black Diamond Therapeutics Inc
NASDAQ:BDTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Black Diamond Therapeutics Inc
NASDAQ:BDTX
|
US |
|
K
|
Kinder Morgan Inc
XMUN:2KD
|
US |
|
I
|
Investec PLC
DUS:IVKA
|
UK |
|
Geberit AG
F:GBRA
|
CH |
|
Lu-Ve SpA
MIL:LUVE
|
IT |
|
Fiserv Inc
NASDAQ:FISV
|
US |
|
T
|
Toyota Industries Corp
XMUN:TAH
|
JP |
|
Bukalapak.com Tbk PT
IDX:BUKA
|
ID |
|
SIG Group AG
SIX:SIGN
|
CH |
|
Clariane SE
PAR:CLARI
|
FR |
|
V
|
Valtecne SpA
MIL:VLT
|
IT |
|
Affirm Holdings Inc
NASDAQ:AFRM
|
US |
|
S
|
SSE PLC
DUS:SCT
|
UK |
|
Iberdrola SA
MAD:IBE
|
ES |
|
Lattice Semiconductor Corp
NASDAQ:LSCC
|
US |
|
Entergy Corp
NYSE:ETR
|
US |
|
Peraso Inc
NASDAQ:PRSO
|
US |
|
Globalfoundries Inc
NASDAQ:GFS
|
US |
|
Workday Inc
NASDAQ:WDAY
|
US |
Wall St Price Targets
BDTX Price Targets Summary
Black Diamond Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BDTX is 10.05 USD with a low forecast of 7.07 USD and a high forecast of 14.7 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BDTX's stock price target?
Price Target
10.05
USD
According to Wall Street analysts, the average 1-year price target for BDTX is 10.05 USD with a low forecast of 7.07 USD and a high forecast of 14.7 USD.
What is the Revenue forecast for Black Diamond Therapeutics Inc?
Projected CAGR
32%
The compound annual growth rate for Revenue over the next 8 years is 32%.
What is the Operating Income forecast for Black Diamond Therapeutics Inc?
Projected CAGR
40%
The compound annual growth rate for Operating Income over the next 8 years is 40%.
What is the Net Income forecast for Black Diamond Therapeutics Inc?
Projected CAGR
22%
The compound annual growth rate for Net Income over the next 8 years is 22%.
